The FDA is launching a new pilot prioritization program for the review of abbreviated new drug applications that would provide faster reviews for generic companies that test and manufacture their products in the US.
- Applicants conducting any required bioequivalence testing in the US and whose products are made in the US using exclusively domestic sources for APIs are eligible for priority review
- Goal is to “spur and reward’ investment in US manufacturing and research and strengthen domestic pharmaceutical supply chain
To view the original source of this information click
To contact the reporter on this story:
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.